Investigators evaluated cognitive outcomes in children with intestinal failure (IF) and at risk for IF as a result of conditions that affect the small intestine.
Study authors determined the impact of pimavanserin on cognitive function in patients with neuropsychiatric manifestations of neurodegenerative disease.
Researchers conducted an 8-week, open-label, single-arm study and a subsequent 2-stage, sequential, parallel comparison study to assess the use of pimavanserin among patients with Parkinson disease and major depressive disorder.
Individuals with severe periodontal disease or edentulism have an increased risk for incident dementia.
At AAIC 2020, 2 presentations separately discussed observing a reduced risk of AD in patients who received the influenza and pneumonia vaccines.
Researchers conducted a randomized clinical trial to assess whether 24 weeks of treatment with rotigotine can modify cognitive functions in patients with mild to moderate Alzheimer disease.
Cardiovascular risk factors are associated with accelerated cognitive decline in midlife.
Reduced circadian rhythmicity is associated with an increased risk for incident Parkinson disease.
The FDA has granted Breakthrough Therapy designation to AXS-05 (Axsome Therapeutics) for the treatment of Alzheimer disease (AD) agitation.
Precision medicine offers a promising therapeutic strategy for patients with Parkinson disease, allowing for tailored treatments which reflect the unique pathophysiology in each patient.
